Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$58.59 USD
+0.21 (0.36%)
Updated Sep 16, 2025 04:00 PM ET
Pre-Market: $58.75 +0.16 (0.27%) 9:06 AM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Protagonist Therapeutics, Inc. has a market cap of $3.64B, which represents its share price of $58.59 multiplied by its outstanding shares number of 62.21M. As a mid-cap company, PTGX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PTGX 58.59 +0.21(0.36%)
Will PTGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Other News for PTGX
Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM
Protagonist Therapeutics announces presentations of icotrokinra data
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
H.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics announces presentations of icotrokinra data